Gyre Therapeutics, Inc. Accrued Professional Fees, Current
Gyre Therapeutics, Inc. (GYRE) had Accrued Professional Fees, Current of $2.18 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Payables and Accruals › Accrued Liabilities, Current
us-gaap:AccruedProfessionalFeesCurrent · last filed 2026-08-07
- 2026-06-30: Accrued Professional Fees, Current $2.18M.
- 2026-03-31: Accrued Professional Fees, Current $2.63M.
- 2025-12-31: Accrued Professional Fees, Current $352.00K.
- 2025-09-30: Accrued Professional Fees, Current $563.00K.
| Period end | Accrued Professional Fees, Current |
|---|---|
| 2026-06-30 | $2.18M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $2.63M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $352.00K 10-Q · filed 2026-08-07 |
| 2025-09-30 | $563.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $862.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $227.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $667.00K 10-K · filed 2026-03-13 |
| 2024-06-30 | $113.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $251.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $837.00K 10-K · filed 2025-03-17 |
| 2023-06-30 | $210.00K 10-Q · filed 2023-08-14 |
| 2022-12-31 | $1.42M 10-Q · filed 2023-08-14 |
| 2021-12-31 | $509.00K 10-K · filed 2023-03-30 |
| 2020-12-31 | $3.98M 10-K · filed 2022-03-31 |
| 2019-12-31 | $2.03M 10-K · filed 2021-03-04 |
| 2018-12-31 | $597.00K 10-K · filed 2020-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |